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The Danish National Database for Asthma: establishing
clinical quality indicators
Susanne Hansen1, Benjamin Hoffmann-Petersen2, Asger Sverrild3,
Elvira V. Bra¨uner1,4, Jesper Lykkegaard5, Uffe Bodtger6,7,8,
Lone Agertoft2, Lene Korshøj9 and Vibeke Backer3*
1Research Centre for Prevention and Health, Rigshospitalet Glostrup Hospital, Glostrup,
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University Hospital, Copenhagen, Denmark; 4Department of Occupational and Environmental Medicine,
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Naestved Hospital, Region Zealand, Denmark; 7Department of Respiratory Medicine, Zealand University
Hospital Roskilde, Region Zealand, Denmark; 8Institute of Regional Health Research, University of Southern
Denmark, Odense, Denmark; 9The Danish Clinical Registries, Aarhus, Denmark
Asthma is one of the most common chronic diseases worldwide affecting more than 300 million people.
Symptoms are often non-specific and include coughing, wheezing, chest tightness, and shortness of breath.
Asthma may be highly variable within the same individual over time. Although asthma results in death only
in extreme cases, the disease is associated with significant morbidity, reduced quality of life, increased
absenteeism, and large costs for society. Asthma can be diagnosed based on report of characteristic symptoms
and/or the use of several different diagnostic tests. However, there is currently no gold standard for making a
diagnosis, and some degree of misclassification and inter-observer variation can be expected. This may lead to
local and regional differences in the treatment, monitoring, and follow-up of the patients. The Danish National
Database for Asthma (DNDA) is slated to be established with the overall aim of collecting data on all patients
treated for asthma in Denmark and systematically monitoring the treatment quality and disease management
in both primary and secondary care facilities across the country. The DNDA links information from
population-based disease registers in Denmark, including the National Patient Register, the National
Prescription Registry, and the National Health Insurance Services register, and potentially includes all asthma
patients in Denmark. The following quality indicators have been selected to monitor trends: first, conduction
of annual asthma control visits, appropriate pharmacological treatment, measurement of lung function, and
asthma challenge testing; second, tools used for diagnosis in new cases; and third, annual assessment of
smoking status, height, and weight measurements, and the proportion of patients with acute hospital
treatment. The DNDA will be launched in 2016 and will initially include patients treated in secondary care
facilities in Denmark. In the nearby future, the database aims to include asthma diagnosis codes and clinical
data registered by general practitioners and specialised practitioners as well.
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A
sthma is one of the most prevalent chronic res-
piratory diseases in children and young adults,
affecting an estimated 300 million people world-
wide (1). The disease is associated with increased morbid-
ity and reduced quality of life, and the costs associated with
this disease in the form of health care and sick-leave
compensation are significant (2, 3).
Although the disease has been known for centuries, a
gold standard diagnostic test for asthma is lacking. In a
specialist setting, the cases are typically characterised by
respiratory symptoms and a positive asthma challenge,
whereas primary care often diagnoses asthma solely
based on symptoms, and possibly also on the effect of
asthma medication. Previous studies have suggested that
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undiagnosed cases, dubious asthma diagnosis, and poor
asthma control are common (4, 5).
The Danish National Database for Asthma (DNDA)
will be launched in 2016 with the overall aim of collecting
data on all patients treated for asthma in Denmark and
monitoring asthma occurrence, the quality of diagnosis,
and management, and has been described in detail else-
where (6). The database is based on existing health care
registers within the Danish health care system, including
the National Patient Register, the National Prescription
Registry, and the National Health Insurance Services
register. Because the Danish health care system is universal
and free of charge for everyone, all patients with asthma
that are diagnosed or treated are therefore potentially
included in the database. The data collected in the
DNDA encompass monitoring the trends in the following
quality indicators: first, conduction of annual asthma
control visits, pharmacological treatment, forced expira-
tory volume in 1 sec, forced vital capacity (FVC), and
asthma challenge testing; second, tools used for diagnosis
in new cases and the proportion of skin prick tests
performed or the measurement of specific immunoglobu-
lin E concentrations in new patients; and third, annual
assessment of smoking status, height and weight measure-
ment, and the proportion of patients with acute hospital
treatment (6).
This paper is not a systematic review but presents
evidence from the existing literature that has formed the
basis for the discussions on the selection of nine quality
indicators taken by the steering committee of the DNDA
embracing specialists in respiratory medicine, paediatrics,
epidemiology, and general practice, representing all re-
gions in Denmark. Due to uncertainty associated with an
asthma diagnosis in young children and due to an overlap
between symptoms of asthma and chronic obstructive
pulmonary disease (COPD) in older patients, the steering
committee has decided that the indicators in the DNDA
will evaluate the quality of care in asthma patients aged
between 6 and 45 years and, therefore, this paper presents
literature focusing on this age range.
Indicator 1: control visits
Introduction
Asthma control is the degree to which the manifestations
of asthma are minimised by therapeutic interventions. The
goal of asthma control is two-fold: First, the goal is to
reduce the frequency and intensity of symptoms that the
patient is currently experiencing or has recently experi-
enced; Second, the goal is to reduce the risk of asthma
exacerbations or of progressive loss of lung function over
time. Level of asthma control is achieved in response
to treatment and determines if the patient’s medication
should be adjusted.
Effect of inhaled corticosteroids in asthma control
In a large randomised study, the Gaining Optimal Asthma
ControL study with asthma control as the primary end-
point, almost 60% of patients achieved disease control
within the first 8 weeks of the start of, or increase in, in-
haled corticosteroids (ICS) (7). Asthma control was
defined by no or few day-time symptoms, no or little use
of beta-2-agonists, morning peak expiratory flow (PEF)
]80% of usual or normal PEF, no night-time wakening
due to asthma symptoms, no exacerbations, no emer-
gency room visits, or no treatment-related adverse events
leading to changes in treatment. Patients were followed
over 52 weeks with gradual up-titration of ICS every
12 weeks (to a maximum of fluticasone 500 mg 12),
followed by a phase of fixed-dose ICS. The overall pro-
portion of patients with well-controlled asthma increased
significantly within the 52-week period. Furthermore, in
another randomized controlled study (RCT) using inhaled
ICS in fixed combination with long-acting beta2-agonist
(ICS/LABA), both as maintenance and reliever therapy
single maintenance and reliever therapy (SMART), the
gain of asthma control has been examined. SMART
achieved greater improvements in inflammatory biomar-
kers, symptom scores, and reliever use in patients treated
with ICS alone with uncontrolled symptoms at the time of
enrolment. Furthermore, SMART has also been found to
prevent development of severe exacerbations (8) and
increased adherence (9).
Frequency of asthma control visits
Global Initiative for Asthma (GINA) guidelines suggest
that the evaluation of asthma control is approached by
assessing two areas (10): first, assessment of the degree
of symptom control, and second, the assessment of risk
factors for poor asthma outcome. However, there are no
clear recommendations regarding the frequency of patient
follow-up. The initial frequency should be determined by
the time-course of improvement in different asthma con-
trol outcome variables. Asthma symptoms have been
shown to be reduced relatively quickly after commencing
ICS treatment. Night-time symptoms are the first to
disappear within a few weeks, and day-time symptoms
typically subside after the first few months (1113). The
greatest effect on forced expiratory volume in 1 sec (FEV1)
can be expected within 4 weeks (14, 15), but there will be
further improvement in FEV1 around 1214 weeks after
starting treatment (16).
Patients with an asthma diagnosis should be monitored
with regular check-ups to ensure adequate symptom control,
ensure normal activity level, minimise the risk of exacerba-
tions, ensure normal lung function and lung development in
children, and minimise side effects of the medication (10).
When exclusively assessing symptom control, the GINA
guidelines suggest that adult patients should be controlled
around 812 weeks after the onset of increased dose of ICS,
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in order to assess symptoms, the use of short-acting beta
agonists (SABA), and lung function (10).
Adherence and inhalation technique
Poor adherence to therapy is a key problem in asthma
management, as poor adherence may have implications for
the development of lung function, poor symptom control,
and increased risk of hospitalisation (1719). Up to 24%
of exacerbations, and 60% of exacerbations requiring
hospitalisation, can be attributed to poor adherence to
controller medication (20).
A recent retrospective register study from 2015, in-
cluding 69,000 participants, reported that almost 20% of
first-time prescribed asthma patients did not redeem their
ICS prescription (21). The same study showed that within
a period of 12 months, the daily requirement of ICS was
only covered approximately 19% of the time. This result is
in agreement with a recent review of the literature from
2015, where adherence was reported to be between 22 and
63% in the included studies (20).
Adherence has been shown to improve after various
types of patient interventions, but no significant effect
on clinical endpoints has been reported. Thus, there is
currently no evidence suggesting that regular follow-up
alone would have a possible positive effect on adherence.
In children, there is evidence that adherence to ICS is
a strong predictor for long-term asthma control (22).
The potential errors using various inhalers are many
(23); over half of the patients, especially the elderly (24)
and young children (25), have poor inhalation techniques
that, at worst, can result in poor asthma control (26, 27).
Most people can learn to use an inhaler correctly after
instruction, but after only a few weeks, the number of
patients who make mistakes in the use of inhaler will
typically increase if techniques are not demonstrated
again (28, 29). Written and oral instructions for using the
inhaler improve inhalation techniques, but this would be
further improved by a physical demonstration by trained
personnel (29). Instruction on the use of the inhaler and
regular training in its use is shown to reduce errors in the
use of inhalers, increase asthma-related quality of life,
and reduce PEF variation (30).
Indicator 2: the use of short-acting beta agonist
and asthma control
Introduction
The pharmacological treatment of asthma is divided into
relievers [inhaled SABA, inhaled ICS, inhaled LABA,
and oral leukotriene receptor antagonists (LTX)]. The
SABA and LABA stimulate the beta-2 receptors, thereby
preventing bronchoconstriction, whereas the preventive
effect of ICS and LTX works through anti-inflammatory
mechanisms. The long-term goal of asthma treatment is
to ensure good symptom control and normal activity,
minimising the risk of acute exacerbations and the
possibility of developing irreversible lung function, while
ensuring the least side effects from the treatment (10).
The treatment of both children and adults is based on a
phased approach to the patient’s symptoms, risk profile,
and needs of SABA. Monotherapy with SABA in adults,
adolescents, and children aged 611 years is used only
for individuals with symptoms less than two times a
week, never against nocturnal symptoms, and is not used
as the sole remedy for exacerbations. According to GINA,
patients who are well controlled and who are not at risk for
future exacerbations should be treated with SABA alone
while all patients with frequent symptoms should start
treatment with ICS.
Despite international guidelines for treatment of asthma,
not all patients are treated successfully and in accordance
with international guidelines. In a recent cross-sectional
study of adult asthma patients, the authors reported that
67% of a group of 493 patients with asthma were not
objectively diagnosed with the disease or were under-
treated, and only 24% who should be treated with ICS
according to GINA guidelines were actually treated with
ICS (5). These results are in agreement with similar
studies of patients with persistent asthma from Europe,
the United States, and Asia that have reported the pro-
portion of patients who are underdiagnosed or under-
treated to vary between 48 and 86%, and the proportion
of patients who do not receive treatment to be around
3584% (17, 3135). The same pattern of inappropriate
treatment of asthma has been observed in children where
lack of treatment with ICS and inappropriate treatment
with oral SABA not recommended by GINA are common
(36, 37). However, in children, a diagnosis is often con-
firmed by treatment with medications, which may explain
part of the apparent over-treatment.
The consequence of insufficient treatment not meeting
clinical recommendations includes poor asthma control (35,
38) and an increased risk of frequent and severe asthma
exacerbations (39, 40). In Denmark, Backer et al. demon-
strated that the proportion of patients with uncontrolled
asthma was 62%, and this typically included patients with
severe asthma requiring asthma treatment step 4 or step
5 according to GINA (35, 41). Several epidemiological
studies show that the proper use of ICS paralleled by low
SABA consumption is negatively associated with asthma-
related hospitalisations and mortality; thus, SABA overuse
is associated with an increased risk of serious exacerbations
and higher asthma-related health care costs (4244). There
is a need for improved monitoring of the use of asthma
medications and of the effect of initiated treatment.
Consumption of SABA as a measure of the degree
of asthma control
The degree of asthma control can be assessed using validated
questionnaires (4547), or by monitoring consumption of
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SABA as proxy for asthma control, since high consump-
tion of SABA is an expression of poor symptom control, as
indicated in previous studies (43, 4850).
The GINA guidelines define SABA overuse as con-
sumption of more than one SABA container with
200 doses per month based on the study by Suissa et al.
having mortality as the major endpoint. The study in-
cluded 12,301 patients aged 554 years who, over a 10-year
period, had retrieved at least 10 prescriptions for asthma
medications. Mortality increased significantly with con-
sumption of more than 1.7 (95% CI 1.42.5) containers
with 200 doses per month, which corresponds to 12 SABA
containers per year, or about 10 puffs per day (51).
Other studies have similarly studied associations be-
tween the use of SABA and asthma control. Davidsen et al.
reported a weak correlation between high consumption
of SABA, 450 defined daily dose (DDD)/year, and
poor symptom control in individuals with and without
prophylactic treatment with ICS. This correlation was not
significant for consumption of SABA B400 DDD/year
(38). Andrews et al. explored the ICS/(ICSSABA) ratio
in 19,512 asthmatic children aged 218 years retrospec-
tively and found that a ratio of B0.5 significantly pre-
dicted emergency room visits and/or hospitalisations (52).
Silver et al. also conducted a retrospective cohort study
including 93,604 patients aged 656 with asthma who were
prescribed asthma medication. It was found that con-
sumption of ]600 doses of SABA over a 3-month period
was associated with an increased risk of emergency room
visits and hospitalisation with exacerbation of asthma (53).
Paris et al. conducted a similar study in 2008 including
2,056 patients and found a significant positive association
between the use of SABA nebulisers and asthma-related
emergency room visits and admissions, but no associa-
tions with non-nebulisers (48). Finally, an American study
found that consumption of more than 36 single contain-
ers of SABA per year was associated with an increased
risk of exacerbations and poorer asthma control and
that this risk increased progressively with consumption
of7 single containers per year (54). They later compared
various surrogate markers as predictors for asthma
exacerbations, and concluded that the number of indivi-
dual containers with SABA provided to the patient was
most useful for predicting asthma outcome followed by the
ICS/(ICSSABA) ratio (55).
Indicator 3: long-acting beta-agonist
use without concomitant ICS
Introduction
The first inhaled beta2-agonists became available in the
late 1940s and contained isoproterenol, which is an agonist
for both beta1 and beta2 receptors. In the 1960s, there
was an epidemic of asthma-related deaths, which was
linked to the use of inhaled isoproterenol. A new epidemic
in the late 1970s was related to the use of fenoterol, an
inhaled short-acting beta2-agonist. The LABAs salmeterol
and formoterol were developed in the late 1980s. With
history in mind, there has been a continuous focus on the
safety of LABA in asthma patients.
Evidence of increased mortality associated with
LABA as monotherapy in patients with asthma
In 2014, a Cochrane review comparing the incidence
of serious adverse events (SAEs) and asthma-related
deaths in patients receiving treatment with salmeterol
and formoterol compared with placebo treatments was
released (56). Data were analysed both as a categorical
effect (salmeterol and formoterol together) and as indivi-
dual effects of salmeterol and formoterol alone. It was
concluded that patients treated with LABA (salmeterol
and formoterol combined) had an increased risk of SAE
and asthma-related deaths compared with placebo. The
results were primarily driven by the salmeterol Multicenter
Asthma Research Trial from 2006 (57) which was inter-
rupted due to higher mortality and increased incidence
of life-threatening asthma-related episodes in the group
of patients treated with salmeterol. Analysis of the data
from this multi-centre study showed that the increased
frequency of deaths and life-threatening asthma-related
episodes was significantly higher in the group of African
Americans without concomitant ICS therapy (57).
There is still some debate about the safety of the use
of LABAICS versus ICS alone. Data have not con-
firmed an increased risk in mortality or SAE for LABA in
addition to ICS. Therefore, it cannot be definitely ruled out
that treatment with LABA in addition to ICS represents
a risk, and additional data are required (56). Large studies
assessing the safety of LABAICS versus ICS alone pro-
mpted by the US Food and Drug Administration are
presently being implemented.
GINA further recommends that, if LABA is indicated,
LABA should be replaced with a combination product
including LABA and ICS in one inhaler to minimise the
risk of a situation where the patient is only compliant
with the LABA. However, no data have been identified
that support this statement.
Evidence regarding LABA as monotherapy
in children
Although several of the abovementioned studies included
data on LABA treatment in children, there are generally
too few data available to enable meaningful conclusions
on the potential increased risk of SAE and mortality
during monotherapy with LABA in children (58, 59).
Recommendations for children are therefore extrapolated
from the adult population.
The use of anticholinergics in patients with asthma
There is no evidence of increased numbers of SAE
or mortality in adult patients using short-term acting
Susanne Hansen et al.
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anticholinergics (6062) or in adolescents ]12 years
of age (63).
Historically, anticholinergics have not been used to the
same extents as beta2-agonists in asthma. Short-acting
anticholinergics (SAMA) may well have shown a significant
but modest bronchodilator and symptom-reduction effect
in asthma (60); however, this is estimated to be inferior
to beta2-agonists (64). In a meta-analysis of studies com-
paring SAMA/SABA to SABA alone, there were no im-
provements in symptoms, lung function, or exacerbation
rate with the addition of anticholinergics (60).
A short-term study examined the safety and efficacy of
long-acting anticholinergics (LAMA) using umeclidinium
as monotherapy in asthma and found a modest benefit of
umeclidinium over placebo in terms of FEV1 area equal to
6090 mL (62). The study did not report prior medication
use and was too short to address exacerbation risk.
Finally, a studyon patientswith inadequate disease control
on regular ICS use reported that the addition of tiotropium
to ICS had greater effect on lung function and asthma
symptoms compared with doubling of ICS dose (65). Later
studies have confirmed that treatment with anticholinergics
as an add-on to ICS or ICSLABA improves lung function
and reduces the number of exacerbations, emergency room
visits, and hospitalisations (66, 67).
Indicator 4: lung function
Introduction
Lung function measurements, including registration
of FEV1 and FVC, constitute the cornerstone of out-
patient visits for asthma patients. There are no absolute
contraindications, and only a few relative contrain-
dications, including a recent acute coronary syndrome
and circumstances which might affect the validity of
the measurements, for example, pain, dementia, and
incontinence.
Validity of spirometry
Spirometry is a standardised and validated measurement.
FEV1 is typically reported as a percentage of the pre-
dicted value (% predicted), based on normal materials
collected and stratified for age, sex, height, and ethnicity.
It is recommended that the staff carrying out spirometry
has undergone relevant training, and they are offered
ongoing maintenance of skills (68). Variability of re-
peated measurements of FEV1 is expected to be maxi-
mally 150 mL. The variation over time is much larger,
and FEV1 in healthy subjects can vary up to 12% from
week to week, and up to 15% from year to year (69, 70).
The relationship between FEV1, symptoms, and
other disease markers
The relationship between FEV1 and severity of symptoms
assessed by standardised questionnaires is low (71, 72),
which is also the case for PEF (73). In addition, quality
of life, as well as inflammation markers, only corre-
lates weakly with FEV1 (74). In contrast, a low FEV1 %
predicted is an independent marker for increased mor-
tality, increased risk of exacerbations, as well as in-
creased risk for the development of irreversible airway
obstruction (75).
Low FEV1 % predicted has been found to be an
independent marker (after adjustment for sex and
smoking) for increased risk of exacerbations requir-
ing emergency room visit or hospitalisation (7679).
Osborne et al. has shown that patients with FEV1 of
6080% predicted had a two-and-a-half times increase
in the relative risk of hospitalisation, compared with
asthmatic patients with FEV1 ]80% predicted. Patients
with FEV1 B60% predicted had an even higher relative
risk (76).
FEV1 over time in patients with asthma
Overall, patients with asthma have lower lung function
than those without asthma due to a reduced growth in
childhood and early adulthood, and/or accelerated loss of
lung function in adulthood (80). An American 25-year
follow-up study of 2,552 participants found that the loss
of lung function was already present before the age of 25
in patients having an asthma diagnosis before age 25,
while the loss of lung function in people with asthma
onset after age 25 was primarily attributable to an
accelerated loss in adulthood (81).
A Danish study found that the loss of lung function in
patients with asthma was 16 mL/year higher than for
people without asthma (82), who are usually assumed to
have a loss of 1826 mL/year (83, 84). However, data
suggest large individual differences in annual loss of
lung function in patients with asthma. There is currently
a shortage of biomarkers that reliably identify patients
(children or adults) at risk of excessive lung function
decline, yet increased bronchial inflammation or symp-
tom burden are identified as risk factors. These include
bronchial hyper-reactivity, frequent exacerbations, per-
sistent symptoms, asthma onset in adulthood, and con-
tinuing high FeNO (despite treatment) (85). Due to the
abovementioned large individual annual variation in
FEV1 measurements over time, a clinically significant
decrease in FEV1 cannot be reliably assessed in time
periods shorter than 35 years (86, 87).
Patients with asthma with a low FEV1% of predicted
value are at an increased risk of developing irreversible
airway obstruction with time (88) which in turn is a risk
factor for increased morbidity (89), increased mortality
(90), accelerated loss of lung function (87), and increased
number of exacerbations (87).
How frequently should FEV1 be measured?
FEV1% of predicted value is considered a prognostic
marker for exacerbations frequency and the risk of
Establishing clinical quality indicators
Citation: European Clinical Respiratory Journal 2016, 3: 33903 - http://dx.doi.org/10.3402/ecrj.v3.33903 5
(page number not for citation purpose)
development of irreversible airway obstruction (91).
GINA guidelines recommend that lung function is
measured at diagnosis and onset of controller therapy
and after 3 months of controller therapy (10). This aids in
clarifying the risk of exacerbations and irreversible airway
obstruction and the optimal FEV1. Recommendations for
subsequent FEV1 measurements are less clear due to the
between-visit variability of FEV1, limiting its use in
adjusting asthma treatment in clinical practice (10).
Indicator 5: verification of the asthma diagnosis
Introduction
There is considerable uncertainty associated with the
asthma diagnosis because there is no ‘gold standard’ for
the disease. The risks of under-diagnosis and over-diagnosis
are clinically relevant (5, 92). An incorrect diagnosis implies
a risk of over-medication and illness behaviour while under-
diagnosis results in increased morbidity. A correct diagnosis
not only reduces the risks of over-treatment and under-
treatment but also seems to affect patients’ understanding
of their disease: patients with ‘objectively’ demonstrated
asthma were more likely to adhere to their controller medi-
cations compared with patients without objectively demon-
strated asthma (93).
Asthma diagnosis in adults and children over 5 years
In accordance with the GINA guidelines, the asthma
diagnosis consists of two steps: The first is identification of
symptom characteristic of asthma and the second is proof
of variable airflow obstruction. The latter requires serial
measurement of FEV1 or, if not available, PEF before and
after reversibility test (SABA, ICS, or oral corticosteroid),
provocation test (exercise, methacholine, mannitol, hyper-
tonic saline, eucapnic hyperventilation), or completion
of PEF diary over several weeks. GINA recommends that
the asthma diagnosis is objectively confirmed but accepts
that an asthma diagnosis is provided in the presence of
characteristic symptoms alone.
The individual tests possess different diagnostic properties.
Due to the lack of a gold standard for measurement
of asthma, it is challenging to compare tests directly,
but evidence for each of the tests is emerging. The diag-
nostic properties of widely used asthma tests in patients
referred from primary care physicians for evaluation of
suspected asthma at a respiratory specialist unit were
compared in a recent study (94, 95). The four tests in-
cluded beta-2 reversibility 12%, PEF variation 20%,
mannitol provocation, and methacholine provocation.
This study underlines that no single test has the optimal
diagnostic strength, and that highest sensitivity and
specificity is obtained with provocation test with metha-
choline and mannitol, respectively.
Indicator 6: allergy testing
Introduction
According to GINA, allergen exposure in sensitised indi-
viduals and in patients with allergic rhinitis is considered
to be a potential modifiable risk factor for increased
severity of asthma in both children and adults. GINA
guidelines recommend clarification of the presence of
allergy in adults as part of risk stratification for poor
asthma outcome, while guidelines in children are less clear.
Clarifying a possible allergic component helps to clarify
the presence of preventive asthma triggers as well as
allergic non-asthmatic comorbidity requiring other ther-
apeutic interventions.
Sensitisation and asthma
Sensitisation to both food and inhalant allergens is very
common among children and young adults. A previous
study found the prevalence of sensitisation to at least
one of the most common allergens to be 43% in children
aged 03 years, and as high as 7880% in children aged
416 years (96). For several decades, numerous long-
itudinal studies have attempted to describe the natural
course of asthma during childhood to adulthood, includ-
ing attempts to clarify the importance of sensitisation in
children with respiratory symptoms. A recent review of
the most frequently cited studies concluded that sensiti-
sation against a number of inhalant allergens is asso-
ciated with persistent asthma symptoms in children (97).
At the same time, only a small number of sensitised in-
dividuals actually develop symptoms defined as asthma
(97, 98). Longitudinal studies report associations between
early sensitisation against inhalant allergens and per-
sistent respiratory symptoms (99103). Simpson et al. has
shown that multi-sensitisation in early age was a strong
risk factor for later development of asthma (104).
In adults, Osborne et al. conducted a prospective
30-months follow-up study and reported that a positive
skin prick test for cat or dog dander was associated with
an increased risk of asthma exacerbation with a relative
risk of 1.49 (95% CI 1.12.0; 76). Another study reported
that sensitisation to house dust mites was associated with
emergency room visits with exacerbations, and increasing
titer of house-dust-mite-specific IgE was associated with
a further increase in the risk of hospitalisations (105).
It seems that in children with airway symptoms, sensi-
tisation to allergens is a strong risk factor for persistent
asthma, although not all children with sensitisation and
airway symptoms develop asthma. Aeroallergen sensitisa-
tion and associated humoral and cellular immunological
apparatus possibly interact with pro-inflammatory co-
factors in the environment, including irritants and viral-
induced infections in childhood, resulting in pro-asthmatic
inflammation (98, 106).
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Allergy, rhinitis, and asthma
Allergologic workup can be used to determine whether
specific allergens affect the patient’s symptoms, and influence
asthma disease progression, variation, and treatment. In
turn, this determines how the patient should be optimally
advised and treated (elimination, allergen-specific immu-
notherapy, anti-allergic drugs).
An association between food allergy and asthma has
been shown, and in combination these increase the risk
of severe reactions and death (107). Rhinitis (allergic or
non-allergic) is present in 6080% of asthma patients, and
accompanying rhinitis is a positive association with asthma
symptom severity and the risk of exacerbations (108).
In patients with severe asthma, the elucidation of
an allergic component is of differential diagnostic rele-
vance (109). In patients suspected of occupational
allergy, clarification is of major importance to identify
symptom-triggering allergens, affecting the patients’
future employment (110).
Prevention
Allergen elimination is a cornerstone in medical allergol-
ogy, as primary, secondary, and tertiary prophylaxis.
Allergen-reducing interventions as secondary prevention
(to avoid symptoms in sensitised subjects) have been
examined in several large-scale studies all showing that it
is possible to reduce indoor allergen concentration, yet the
results regarding the clinical impact have been contra-
dictory (111, 112). In the Manchester Asthma Allergy
Study, it was found that the intervention group, in which
the concentration of dust mites was significantly reduced,
had an increased risk of allergy against house dust mites
(111). There is no sufficient data available to recommend
interventions to regulate the exposure to common aller-
gens with the purpose of preventing allergy and asthma,
both with respect to prenatal and postnatal exposures.
A reduction in allergen exposure as tertiary prevention
(treatment of clinical symptoms) has also been discussed.
Some allergens can effectively be avoided by a sensitised
individual including animal dander, while outdoor aller-
gens such as pollens are almost impossible to eliminate
without extensive intervention. The effect of different inter-
ventions in patients with house dust mites was examined in
a systematic review that included 54 studies and found no
effect on peak flow, symptoms, or medication use (113). A
meta-analysis that examined the effect of impermeable
sheets showed no significant effect on the relative risk for
sensitisation against house dust mites, wheezing, asthma,
allergic rhinitis, or allergic dermatitis (105). Other clinical
studies indicate that tertiary prevention may have a role in
the treatment for asthma with verified allergy: improve-
ment in bronchial hyperactivity and symptoms control
after interventions consisting of a clean environment
without dust mites (111, 114116). Yet, it remains unclear
which interventions are most effective. According to
Custovic et al., the impact of allergen-reducing interven-
tions on several levels in meticulously selected patients has
not been clarified (117).
In conclusion, it seems reasonable to attempt allergy
avoidance as tertiary prevention in selected patients on
the basis of individual symptoms, sensitisation patterns,
and exposures.
Allergen-specific immunotherapy
Patients with allergy and asthma may benefit from allergen-
specific immunotherapy (SIT). In contrast to elimination
and conventional medical therapy, SIT modifies disease
course so that risk of asthma is reduced in non-asthmatic
children and adults treated with SIT for allergic rhinitis
(118). In patients with allergic asthma, SIT reduces asthma
symptoms and the need for controller therapy (118120).
SIT is not recommended in patients with uncontrolled
asthma, but new data suggest that SIT in combination with
omalizumab treatment may improve the clinical effect and
reduce the risk of severe side effects (121).
The international guidelines on rhinitis suggest that
SIT is considered in severe seasonal rhinitis, and in
moderate to severe perennial rhinitis (122). In Scandinavia,
the relevant aeroallergens are birch pollen, grass pollen,
and house dust mite allergen (dermatophagoides ptero-
nyssinus and farina; 123), but the pattern of allergen
sensitisation differs between geographic areas.
Treatment with SIT is currently limited by therapy
factors (few different vaccines available, costs, and long
duration of treatment), disease factors (multi-sensitisa-
tion, co-existence of allergic and non-allergic asthma, and
non-responders), and patient factors (adherence, costs,
inability to reduce other asthma triggers including allergen
avoidance; 124).
It remains unknown if all relevant patients with asthma
are also offered SIT, but with respect to patients with
allergic rhinitis, only a minority of highly symptomatic
patients is offered SIT (125). New measures such as sub-
lingual immunotherapy, governmental refunding, in-
creased awareness in primary care, and careful selection
of patients might improve the use and success of SIT (126).
Indicator 7: smoking
Introduction
More than 65 years ago, Doll and Hill first reported that
active smoking is associated with significant health risks
including lung-cancer development (127), and in subse-
quent decades, the harmful impact of passive smoking
has also been highlighted. The underlying pathophysiolo-
gical mechanisms include a combination of changes in the
pulmonary immune system, pro-inflammatory response,
and increased oxidative stress (128, 129).
Over the past decades, the proportion of smokers
has declined, both among adolescents and adults (130)
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and in children exposed to passive smoking (131). Since
2003, 177 countries have joined the WHO Framework
Convention for Tobacco Control with the objective of
gaining control of the global consumption of tobacco
and thereby reducing mortality and comorbidity asso-
ciated with smoking. The effect of this law enforcement
in adults was studied in a meta-analysis in 2012 which
concluded that the legislation enforcement has been
associated with a significant lower risk of asthma and
respiratory infections (132). In children, anti-smoking
laws have been associated with a significant reduction in
the number of asthma-related hospital admissions (133).
Passive smoking in children
The prevalence of passive smoking in children and
adolescents has generally been declining over the past
decades, but a recent report from the United States shows
that the fall is exclusively observed in children without
asthma, while children with asthma continue to be ex-
posed to passive smoking to the same extent (134). In
addition, parents of children with asthma tend to under-
report the amount of second-hand smoke their children
are exposed to (135).
Two systematic reviews from 2014 concluded that
exposure to prenatal and postnatal passive smoking in
creases the riskof asthma diagnosis, asthma symptoms, use
of beta-2 agonists and leukotriene-receptors, and exacer-
bations in children (136, 137). The included studies were,
however, of varying quality, often had different aims, and
used different definitions of asthma (136, 137). Further-
more, it is challenging to ascribe the isolated impact of
prenatal and postnatal exposure, respectively, since par-
ents who smoke during pregnancy, often smoke after birth
(138). The conclusions from the reviews were supported by
a meta-analysis that reported an association between
passive smoking and doctor-diagnosed asthma in children
with a pooled OR 1.32 (95% CI 1.231.42; 139). Recently,
published studies describe similar associations of an in-
creased risk of asthma outcomes or reduced lung function
after exposure to passive smoking in children (140148).
The association between exposure to passive smoking
in childhood and sensitisation to aeroallergens is less
clear. Ciaccio et al. failed to find an association (149). A
systematic review from 2014 found an increased risk
of sensitisation in pre-school children based on a meta-
analysis of 6629 individuals, although the effect was modest
(OR1.20, 95% CI: 1.051.38 for specific IgE and
OR1.30, 95% CI: 1.051.61 for skin prick test). The effect
in children older than 7 years was not significant (150).
Smoking in adolescence and adulthood
The impact of smoking in adolescents is poorly studied.
Lawson et al. described a link between passive smoking
and the onset of asthma in adolescence among 956
Canadian subjects aged 1218 years with no history of
asthma diagnosis but found no significant association
between active smoking and the development of asthma
in adolescence (151). A cross-sectional study in 2009 that
surveyed 1,492 Korean adolescents aged 1516 years
found that active smoking was associated with wheezing
within the past year (OR4.5 95% CI 1.513.2), and
wheezing with physical activity in the past year (OR8.7
95% CI 3.720.9; 152).
In adult patients with asthma, active smoking is as-
sociated with more pronounced symptoms, reduced asth-
ma control, and reduced efficacy of treatment with ICS
(153), and they experience frequent exacerbations, epi-
sodes of wheezing and nocturnal symptoms, and higher
mortality (154). There is evidence for more frequent
asthma-related admissions in adults who are current and
former smokers compared with never smokers (155).
There is substantial evidence of the harmful impact of
active smoking in asthma patients, but whether smoking
is associated with an increased risk for the onset of
asthma in adults is controversial. Many cross-sectional
studies have shown a link between smoking and the onset
of asthma, but these studies cannot explain a causal
relationship. Several cohort studies support this, while
others have found no relationship, and one describes a
lower incidence of asthma in current smokers (129, 156).
The most recent published study of the association
between asthma and tobacco is a large cohort study
from the United States, which followed 46,182 people
without asthma diagnosis at baseline and with an average
follow-up of 14.7 years. This study found a clear link
between active smoking and the development of asthma,
as well as an increased risk of developing asthma in non-
smokers exposed to second-hand smoke (129).
Long-term impact of smoking on asthma
The long-term consequences of active smoking in asthma
patients have not yet been fully clarified, and present
conclusions are contradictory. Some studies describe a
more rapid decline in lung function in adult asthma
patients who smoke, and early development of COPD in
some (157), while studies from the European Community
Respiratory Health Survey do not support this (158).
However, there are studies that clearly show that smoking
cessation is associated with improvement in lung function,
slower decline in lung function, and better asthma control
(154, 158). It has further been shown that smoking
accelerates the decline in FEV1 in patients with asthma,
and that treatment with ICS can reduce this decline in
FEV1 in asthmatics who smoke (159, 160).
Indicator 8: height and weight
Introduction
For several years, it has been debated whether systemic
treatment with inhaled steroids affects the growth (height)
in children. In 1980, suspicions were based on individual
Susanne Hansen et al.
8
(page number not for citation purpose)
Citation: European Clinical Respiratory Journal 2016, 3: 33903 - http://dx.doi.org/10.3402/ecrj.v3.33903
cases, while early trials and meta-analyses failed to detect
a significant effect on height development (161, 162).
However, in subsequent years, several short-term studies
have reported a significant reduction in height develop-
ment (growth) after a few months of treatment primarily in
pre-pubertal children (163). Consequently, the US Food
and Drug Administration decided that the patient infor-
mation leaflets of inhaled steroids should include a clear
warning that the treatment could potentially constrain
growth (height; 164).
Evidence of an effect on height after treatment
with ICS
In a recent Cochrane review of 25 randomised trials with
a total of 8,471 children with mild to moderate asthma,
who were treated with ICS over a period of 3 months
to 46 years, it was found that the regular use of ICS in
low to moderate dose over a 1-year period reduced the
growth rate by 0.48 cm/year (95% CI 0.65 to 0.30)
and the absolute growth by 0.61 cm (95% CI 0.83 to
0.38) compared with a control group treated with
placebo or non-steroid. The reduced growth was most
pronounced in the first year, after which the effect was
less pronounced (165).
In 2014, the dose dependence of treatment with ICS
and the reduced length growth was examined in another
Cochrane review, which reviewed 10 randomised trials
that included a total of 3,394 pre-pubertal children with
mild to moderate asthma who were treated with ICS
monotherapy or ICS in combination with LABA. Treat-
ment with a low to moderate dose (200 mg HFA beclo-
methasone equivalent) was associated with a reduction
in the growth rate by 0.20 cm/year (95% CI 0.020.39)
after 1252 weeks of treatment compared with those
treated with a low dose (50100 mg HFA beclomethasone
equivalent; 166).
Whether ICS treatment is given fixedly or intermittently
is also important as highlighted in yet another Cochrane
review from 2013. This meta-analysis, included 278 pre-
school children and 330 school-age children, and showed
a significant reduction in longitudinal growth by 0.41cm
(95% CI 0.130.69) in children treated with regular daily
ICS (budesonide or beclomethasone) of 4452 weeks, com-
pared with intermittent therapy over 4452 weeks (167).
It is unclear whether the final height in adulthood is
influenced by long-term treatment with ICS as present
studies with follow-up to adulthood describe conflicting
results. The largest study, The Childhood Management
Programme, examined the final height of 943 of the 1,041
participants aged 513 yearswith randomised treatment with
budesonide 400 mg/day, 16 mg nedocromil/day or placebo
with mean treatment duration of 4.3 years. The study found
an average height reduction of 1.20 cm (95% CI 1.90 to
0.50) in the final height compared with placebo (168).
In contrast, Agertoft et al. found that normal final height
was achieved in 142 Danish children with asthma who were
treated with budesonide in a mean dosage of 412 mg/day over
an average period of 9.3 years (169).
Obesity and asthma in children
It has been shown that children with asthma are at a
higher risk of developing obesity compared with children
without asthma (170). It is unclear whether child obesity
precedes the asthma disease, or overweight occurs as
a result of inactivity due to respiratory symptoms, or
if overweight is an asthma phenotype as several long-
itudinal studies have reported that children who were
overweight at inclusion or became obese during the study
had an increased risk of asthma symptoms and asthma
diagnosis (171). In a meta-analysis from 2013, including
six studies with a total of 18,760 children aged 618 years,
it was shown that child obesity increases the risk for the
onset of asthma (172).
Obesity in children with asthma is associated with
negative health consequences, including increased risk
of hospitalisation, longer convalescence during hospitali-
sation for exacerbation, and more pronounced symp-
toms compared with normal-weight children with asthma
(173, 174). Pharmacological treatment has also been
shown to be compromised with a poorer response to ICS
and low-dose theophylline in children with obesity, al-
though there was a slightly increased response to mon-
telukast (171). In children with asthma, weight loss
interventions may improve lung function, asthma control,
and quality of life (175178).
Obesity and asthma in adults
The link between obesity and the prevalence of asthma
was clearly shown in a meta-analysis in 2007 including
333,102 adults, and the result showed a doseresponse
relationship between increasing body mass index (BMI)
and the incidence of asthma (179). In adults with asthma,
obesity is associated with a range of adverse asthma out-
comes, including more pronounced symptoms, increased
absenteeism from work, increased consumption of reliever
medication, a lower probability of good asthma control,
poorer response to anti-asthmatic treatment, and in-
creased risk of asthma exacerbations that require treat-
ment with systemic steroids (180, 181).
Some data suggest that asthma in obese subjects should
be perceived as a distinct phenotype where symptoms
remit after weight loss, including improvements in lung
function, better symptom control, lower need for medica-
tion, and fewer admissions (180).
The pathophysiological basis for the association be-
tween obesity and asthma is not yet established, but
existing theories are based on the fact that obesity is a
pro-inflammatory state. It has been shown that isolated
obesity without accompanying comorbidity is associated
with a slight systemic inflammation and increased oxida-
tive stress. These relationships are thoroughly examined
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in two recent reviews of Ali et al. (180) and Sutherland
et al. (182). Therapeutic weight loss in adults with asthma
was reviewed in a Cochrane review in 2013 and concluded
that weight loss can reduce asthma symptoms and use
of reliever medication, but the studies also had significant
methodological limitations at high risk of bias and de-
ficient data to draw firm conclusions (183).
Indicator 9: acute hospitalisation
Introduction
Asthma is a leading cause of acute hospitalisation among
children. In an inter-European survey of 2000 randomly
sampled patients (of which 753 children and 2050 adults
had asthma), researchers found that 18% of children and
11% of adults with asthma had at least one contact to
the emergency room within the preceding 12 months (184).
In addition, 7% of the entire included asthma population
had been hospitalised (defined as a minimum of one night)
due to asthma within the preceding year. In a Portuguese
population survey from 2015 of asthmatic children and
adolescents aged between 6 and 17 years, 27.7% had at
least one hospitalisation of more than 24 h during their life
(185). Of those who had contact with the emergency room
with asthma symptoms, it was estimated that almost 10%
will subsequently be hospitalised (186, 187).
The average hospitalisation duration in 2003 due to
asthma was estimated to last 0.26 days in adults (188) and
2.6 days in children (189). However, figures vary consider-
ably from study to study and a Danish study including
100 adults with exacerbations concluded an average time in
the emergency room of 10.7 h, while an in-patient visit
took on average 3.6 days (190). The subsequent cost of
hospitalisations due to asthma is high (188).
Emergency room visits are most common in asthma
patients with uncontrolled disease, but also occur among
people with otherwise mild or well-controlled asthma
(191193). There are large individual differences in the
number of calls to the emergency room with asthma,
some asthma patients are rarely or never seen in anything
but the primary sector, others have more annual un-
planned contacts (194, 195). Women are over-represented
in the group of persons requiring hospitalisation for
asthma (196).
Exacerbations
In most drug studies in which admissions or contacts to
the emergency room due to asthma are detected, the
hospitalisation/emergency room visit is rarely the pri-
mary endpoint, but is included as part of the definition of
an ‘exacerbation’. The criteria for exacerbation and
severity of these vary somewhat from study to study
(197), but in a joint working document of the American
Thoracic Society and European Respiratory Society
published in 2009 (197), an exacerbation is defined as:
‘episodes that are troublesome to patients, and that
prompt a need for a change in treatment’. The document
further describes in detail how moderate and severe
exacerbations are defined in children and adults.
Causes of exacerbations
Exacerbations are mostly triggered by well-known risk
factors such as viral infection [up to 85% of exacerbations
in children and 60% in adults, particularly rhinovirus
(198), allergens or pollution (199)]. The main risk markers
for exacerbation in both children and adults include:
previous severe exacerbation (OR6.33 in adults) (200),
overuse of SABA and inadequate treatment with ICS,
low FEV1 (79), socio-economic factors, pregnancy (201),
tobacco exposure (202), irreversible airway obstruction,
eosinophilia (203), obesity, severe rhinosinusitis (204),
and hypersensitivity to non-steroidal anti-inflammatory
drugs (205, 206). Most of these risk factors are listed in
the GINA guidelines and therefore frequent evaluation of
these risk factors is recommended.
The impact of exacerbations
The ultimate consequence of exacerbation in rare cases is
death (207). In children, the most common cause is the
absence of preventive treatment with ICS, besides poor
adherence, severe atopy, and food allergy (207, 208).
Exacerbations reduce the quality of life (209) and lead
to an increased loss of lung function. In a cohort study,
it was found that asthmatics with at least one severe
exacerbation per year had an increased loss in FEV1 of
30.2 mL/year (210).
In an American study of children and adolescents with
and without asthma, asthmatics had more annual sick
days than non-asthmatics (9.2 vs. 7.9 days) (211). The
same difference was also found in another US study
in which asthmatic children had an average of two
more days of absence from school compared with non-
asthmatics (212). Figures from Sweden published in 2004
showed that 34% of children and 13% of adults had at
least one day of absence due to asthma (213). In line with
this, a study published in 2002, including almost 2,600
people with asthma, found an average absence per year
due to asthma of 2.1 days (214). Finally, in Denmark, a
study estimated the production loss due to asthma sick
leave to be more than US$40 million annually (188).
Summary and discussion of the main findings
DNDA is a clinical quality database with the overall aim
to continuously collect data on all patients with asthma,
who are diagnosed, monitored, or treated for the disease
anywhere in Denmark. DNDA links information from
three nationwide registries of administrative records in
the Danish health care system providing a tool to con-
tinuously collect the data on all patients with asthma (6).
The steering committee of the DNDA has chosen a range
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of indicators that constitute the quality parameters.
In this article, the literature supporting each of these
indicators has been presented. In the following, a brief
summary of the evidence is presented along with a
description of the nine quality indicators in the DNDA
and the standards for documented quality of asthma
management that have been set by the steering committee
to form good quality. The standards expressed as a per-
centage can be high or low depending on whether the
direction of the improvement is upwards or downwards,
respectively. The standards may be modified continuously
if new evidence emerges or if the steering committee sets
new goals for good quality. The standards described here
therefore constitute an initial attempt that will be used in
the first report of the DNDA to be published in 2017.
Ongoing revisions to the indicators or/and the standards
can therefore be expected in future reports.
The first quality indicator in the DNDA is ‘control
visits’. There is general consensus that asthma control
visits are important elements in asthma care to ensure
symptom control and assessment of risk factors for
exacerbations. It is known that a rigorous approach aiming
for asthma control gives a near-normal quality of life
and reduces the risk of exacerbations (7). However,
there remains no clear recommendation regarding the fre-
quency of asthma control visits. To ensure a reduction
in symptoms, normalisation of FEV1, and to clarify the
best score on spirometry, it is reasonable to complete
control visits 3 months and 12 months after diagnosis
and initiation, respectively, or titration of anti-asthmatic
therapy. The optimal frequency of subsequent asthma
control visits differs among asthma patients based on
individual needs. We found no evidence that asthma health
care visits exclusively for monitoring lung function affect
symptom control. Adherence and inhalation techniques
are essential for achieving asthma control and should be
assessed and trained regularly (20, 21). It may be appro-
priate to follow patients with frequent exacerbations or
risk of exacerbations closely in order to intervene on
modifiable risk factors.
Despite the conflicting findings in the literature, the
steering committee has decided that indicator 1 in the
DNDA will quantify the proportion of asthma patients,
who are monitored and registered annually with a control
visit. Initially, the standard to be met has been set to]80%
but can be changed in case new evidence regarding control
visits emerges.
The second and third indicators in the DNDA are
related to pharmacological treatment. Available studies
show that asthma is underdiagnosed and undertreated in
both children and adults (5, 31, 32, 34, 35). Undertreated
asthma leads to reduced asthma control and increases the
risk of exacerbations, hospitalisation, and increased health
care costs, emphasising the need for identifying these
individuals (40, 41). Because reasons for the inadequate
treatment of asthma include the health professional’s lack
of adherence to clinical guidelines, it is reasonable to assess
the pattern of prescriptions of anti-asthmatic therapy.
Since establishment of the Danish Civil Registration
System in 1968, all citizens of Denmark have a unique
Personal Identification Number (CPR number). All
medical, social, and other administrative public records
use this unique number to identify citizens: thus, this
number allows accurate linkage between registers. The
Danish Registry of Medicinal Product Statistics has col-
lected data on prescription drugs since 1995 and contains
information on patients’ CPR number prescription date,
specific anatomical therapeutic codes of the type of drug,
and amount in dosage numbers. However, this registry has
not yet been used for systematic monitoring of treatment
of asthma. Prescription data on SABA can be used as a
surrogate marker of poor asthma control and predict
asthma exacerbations, but we found large differences of
the reported SABA prescription associated with the
negative outcomes (4853, 55). Based on the available
literature, it has been decided by the steering committee to
let indicator 2 in the DNDA evaluate the proportion of
asthma patients, who are currently not treated with ICS
despite a high consumption of (600 DDD per year)
SABA. The standard has been set to 510%. Present
GINA guidelines do not support the use of LABA or
LABA as monotherapy or LABA/LAMA in combination,
making these prescription patterns possible surrogate
markers of quality of asthma treatment also. It has been
decided that indicator 3 in the DNDA will evaluate the
proportion of asthma patients who are using LABA,
LAMA, or LABA/LAMA without a concurrent con-
sumption of ICS. The standard has been set to 51%.
Lung function constitutes indicator 4. Spirometry is
a standardised and validated tool to measure lung func-
tion and is widely used in the assessment of asthmatics.
However, FEV1 only weakly reflects the amount of
the symptoms or underlying airway inflammation. FEV1
is a prognostic marker for the number of exacerbations
(particularly FEV1 B60% predicted), development of
irreversible airway obstruction and death (7779). To be
able to monitor changes in FEV1 over time, repeated
measurements with the assessment of the patient’s best
FEV1 early stage is required. Once the individual optimal
FEV1 is assessed, it is recommended to reassess regularly,
but because of individual variations in FEV1 we have
found no evidence for progressive monitoring with FEV1
measurements more than every 35 years in adults.
Despite this fact, the steering committee has decided that
indicators 4a and 4b in the DNDA will measure the
proportion of patients who are currently treated for
asthma in out-patient clinics who have their lung function
measured annually. The standard has initially been set
to 98%. For incident patients, the lung function should
be measured within 6 months before the first asthma
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diagnosis or 6 months after the first diagnosis, and for
patients aged 617 years, the standard has been set
to ]98%, whereas for patients aged 1845 years, the
standard has been set to ]80%.
Verification of the asthma diagnosis constitute in-
dicator 5. We found evidence supporting the fact that an
objective confirmation is important to ensure correct
diagnosis, treatment, and follow-up. Furthermore, a
recent, yet unpublished, study indicates that asthmatics
that did not receive a thorough and objectively demon-
strated asthma diagnosis are less likely to use the pre-
scribed anti-asthmatic treatment (93). There are several
different tests that can be used in the diagnosis of asthma,
and the various diagnostic tests have overlapping diag-
nostic patterns reflected by differences in the sensitivity,
specificity, positive predictive value, and the negative pre-
dictive value. The steering committee has decided that
indicator 5 in the DNDA will quantify the proportion of
incident asthma patients who have a reversibility test, a
provocation test, or an exertion test performed within 6
months before and 6 months after the initial diagnosis for
asthma. The standard has been set to ]80% for all patients.
Indicator 6 concerns allergy testing. Allergic sensitisation
is common in patients with asthma, and sensitisation against
inhalant allergens in children with asthma is associated with
persistent asthma symptoms (215, 216). Allergy testing in
individuals with asthma is relevant for risk stratification of
patients, as sensitisation against inhalant allergens is asso-
ciated with an increased risk of exacerbations and because
allergic comorbidity is shown to be associated with more
pronounced symptoms of asthma. It is always appropriate
to determine whether the indications for specific immu-
notherapy are fulfilled. Allergen elimination has been
debated for centuries because of conflicting results, but
may be appropriate in selected cases. Indictor 6 in the
DNDA will evaluate the proportion of incident asthma
patients who have a skin prick test or quantification of
specific IgEs performed within 6 months before and 6
months after the initial diagnosis. The steering committee
has decided that for patients aged 617 years, the standard
to be met is ]98%, whereas for patients aged 1845 years,
the standard has been set to ]80%.
Indicator 7 is related to smoking. There is evidence
that passive smoking in childhood is associated with the
development of asthma, and in children with asthma
associated with more pronounced symptoms, greater use
of asthma medications, and higher risk of exacerbations
(217221). Both active and passive smoking in adults
increases the risk of developing asthma, and active
smoking in adults with asthma is associated with more
pronounced symptoms, poor asthma control, an acceler-
ated decline in lung function, and reduced efficacy of
treatment with inhaled steroids, as well as more frequent
exacerbations and higher mortality (152159, 222).
Intervention in clinical practice has been shown to be
effective and should be practised. Both passive and active
smoking should be discussed with the patient by relevant
clinical contacts both in patients with and without asthma.
Smoking legislation reduces tobacco-related disease and
smoking-related hospitalisations (132, 133). The steering
committee has decided to let indicator 7 in the DNDA
quantify the proportion of asthma patients who are
inquired about their smoking status at least once a year.
The standard for all patients has been set to ]80%.
Indicator 8 concerns weight and height measurements.
This indicator is included because of evidence that treat-
ment with ICS may result in a modest dose-dependent
reduction in longitudinal growth in children 12 years
after the initial treatment is started, but it is unclear
whether the final height is affected, as current data are
conflicting (163, 164).
Obesity in children and adults with asthma is asso-
ciated with significant adverse effects on asthma disease
and weight loss should be recommended in the treatment
of asthma in both obese children and adults. BMI should
therefore be determined at a minimum when the diag-
nosis is made (171174). It has been decided to include
two indicators on height and weight measurements in the
DNDA. Indicators 8a and 8b will evaluate the proportion
of asthma patients who have their height and weight
measured, respectively, at least once a year. Indicator
8a will only be evaluated in patients aged 617 years. The
standard has been set to ]80%.
Finally, indicator 9 in the DNDA is related to hospitals
admissions. We found evidence that admissions to the
emergency room and/or hospitalisations due to asthma
are frequent.
Exacerbations are linked to increased risk of death,
quality of life, increased loss of lung function, and in-
creased costs for health. In the GINA guidelines, it is
recommended that the risk factors for exacerbations are
regularly evaluated in all patients with the purpose of
preventing hospital admissions. In the DNDA, indicators
9a and 9b will quantify the proportion of patients with
asthma currently treated who end up in the hospital with
an acute admission for a duration of 51 day and 1
day, respectively. No specific standard has been set.
The steering committee of the DNDA believes that a
continuous, systematic collection of relevant clinical infor-
mation is needed to improve asthma treatment in Den-
mark. This includes targeting the use of diagnostic tools in
suspected asthma cases and standardising treatment of the
same level of the disease, reducing over-treatment and
under-treatment, and ensuring better continuity in the
follow-up of asthma patients. The DNDA will potentially
hold a unique set of information, including development in
lung function, use of medication and clinically relevant
endpoints like exacerbations in an asthma population that
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includes all sectors of the nationwide health care system
in Denmark.
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